Camrelizumab/rivoceranibVarious toxicities: 4 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1939卷 / 1期

关键词：

D O I：

10.1007/s40278-023-31534-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：126 / 126

相关论文

共 50 条

[31] Irinotecan/rivoceranibVarious toxicities: case report
Reactions Weekly, 2019, 1734 (1) : 296 - 296
[32] Capecitabine/gemcitabine/rivoceranibVarious toxicities: case report
Reactions Weekly, 2019, 1737 (1) : 75 - 75
[33] RivoceranibVarious toxicities
Reactions Weekly, 2024, 2000 (1) : 320 - 320
[34] RivoceranibVarious toxicities
Reactions Weekly, 2024, 2017 (1) : 445 - 445
[35] RivoceranibVarious toxicities
Reactions Weekly, 2024, 2007 (1) : 303 - 303
[36] Irinotecan/paclitaxel/rivoceranibVarious toxicities: case report
Reactions Weekly, 2021, 1875 (1) : 180 - 180
[37] Carboplatin/etoposide/rivoceranibVarious toxicities: case report
Reactions Weekly, 2018, 1717 (1) : 80 - 80
[38] RivoceranibVarious toxicities and development of resistance: case report
Reactions Weekly, 2019, 1737 (1) : 258 - 258
[39] Programmed-cell-death-1-receptor-antagonists/rivoceranibVarious toxicities: 3 case reports
Reactions Weekly, 2020, 1833 (1) : 331 - 331
[40] Osimertinib/rivoceranibVarious toxicities and lack of efficacy: case report
Reactions Weekly, 2021, 1871 (1) : 336 - 336

← 1 2 3 4 5 →